Breaking AI & Tech News Analyzed

The Power of Football in RecoverySarah Rhind, a 42-year-old goalkeeper and Street Soccer charity coordinator, has a powerful message about how football saved her from heroin addiction. In her recently published autobiography, "Scars Under The Jersey," Rhind details her journey through addiction, recovery, and the transformative role football played in her life. "I can wholeheartedly say that without it I wouldn't be in the position that I'm in now – if I was even lucky enough to still be here," she states emphatically.From Participant to Coordinator: Football as LifelineWhat makes Rhind's story particularly striking is her journey from participant to coordinator at Street Soccer, a charity that provides free sessions for at-risk and socially disadvantaged people. Before working for the organization, Rhind was a participant who relied on the weekly sessions to stay clean. "There were times where I'd come through a really rough weekend, struggling with thoughts of using and relapsing but hadn't done it," she recalls. "There were many times where the reason was literally: 'If I use, I can't go to football on Tuesday.'"Mental Health and the Pitch: A Sanctuary from NoiseRhind describes football as a sanctuary from the "mental noise" that consumed her life. "My mind is 24/7 from the minute I wake up to the minute I go to sleep at night; it's 20 tabs open and they're all about different things," she explains. "When I'm on the pitch and playing football the focus is just on that, because that was most important. It's like a transition happens. I get my boots on and step on to the pitch and I find it is the only place that I am able to leave the mental noise."Breaking Barriers: Women's Football and InclusionNow representing Scotland at international events like the Homeless World Cup (2015) and playing in the Scottish top flight with Hamilton Academical, Rhind is passionate about creating opportunities for women in football. She notes that women of her age have "missed out so much" compared with younger generations benefiting from the growth of the women's game. "I hear all the time: 'I'm not fit enough, not strong enough, I can't play football,'" she says. "When did society become so about having to be really good at something that you can't just try it or to have fun with it?"The Healing Power of StorytellingWriting her autobiography was a cathartic experience for Rhind, who found the process to be "an incredible platform for healing." She particularly struggled with documenting moments of suicidal thoughts, noting that "it had taken me a couple of weeks to actually be able to write a sentence out about being suicidal." The act of writing, however, became therapeutic. "I just wrote it and I remember it so clearly: I just sat and looked at that sentence and realised what a powerful form of therapy that process had been," she reflects.A New Chapter: Continuing the JourneyFor Rhind, recovery is an ongoing process. "Life is hard and that's always going to be the case; things are going to keep happening," she acknowledges. "But, hopefully, I can keep building my toolbox of coping mechanisms for dealing with those things when they come, and keep talking." Through her work with Street Soccer and sharing her story, Rhind continues to help others find their path through darkness, using football as both a literal and metaphorical lifeline.

Podcast Overview: Red‑Light Masks and Ageing ClaimsThe Guardian’s latest science podcast asks the question, “Is it true that red‑light therapy masks prevent wrinkles?” It invites listeners to explore the evidence behind a popular anti‑ageing gadget.What the Episode CoversIntroduction to red‑light therapy and its purported skin‑benefits.Interviews with dermatologists and researchers discussing clinical findings.Consumer perspectives on the rise of at‑home light‑mask devices.Current Evidence LandscapeWhile some small studies suggest modest improvements in skin texture, the podcast notes the lack of large‑scale, peer‑reviewed trials confirming long‑term wrinkle reduction.Implications for Consumers and the Beauty IndustryThe discussion highlights a growing market for home‑use light devices, prompting regulators to consider clearer labelling and efficacy standards.Looking Ahead: Research and RegulationFuture episodes may track upcoming clinical trials and potential guidance from health authorities on the safe use of red‑light masks.

The Rise of Sound Baths in Wellness Culture In an era where digital detoxes and mindfulness practices have become mainstream, a new wellness trend has emerged: sound baths. These experiences, where participants pay to lie on mats while practitioners play singing bowls, chimes, and gongs, have seen online interest rise exponentially in the last decade. From Sydney Harbour settings to high-end wellness clubs with surround-sound chambers, the industry is capitalizing on claims that these sonic experiences can "soothe and calm your nervous system" with sounds that "penetrate every cell in your body." But as this trend grows, questions arise about whether these expensive experiences deliver on their promises. The Science Behind Sound and Relaxation "There's a rich field of music psychology that's all about the impacts of different types of sounds on human psychology and human physiology," explains Dr Vince Polito, a senior lecturer in psychological sciences at Macquarie University. Experts suggest that while specific frequencies may not have the mystical healing properties claimed by practitioners, the experience can still be beneficial. Dr Sandra Garrido, a senior research fellow at the University of Sydney's school of psychology, notes that "like anything in the wellness space, its benefits can definitely be talked up." The effects of sound or music on wellbeing largely relate to how we perceive and interpret those sounds, rather than specific types or frequencies. Research Evidence on Sound Meditation Studies on sound baths and similar practices offer some insight into their potential benefits. A 2016 observational study found that people who participated in a meditation session involving Tibetan singing bowls reported feeling less tension, anger and fatigue afterward. Another randomized controlled trial in breast cancer patients linked Tibetan sound meditation to improved cognitive function and mental health. However, researchers note that mindfulness meditation itself has been independently linked to improvements in anxiety, depression and insomnia, making it difficult to isolate the specific effects of sound. Sound Baths vs. Music Therapy While sound baths have gained popularity in wellness circles, they differ significantly from music therapy, a regulated profession with a long history of therapeutic use. "There are long histories of using music and sound in therapeutic ways," says Dr Amanda Krause, a senior lecturer in psychology and president of the Australian Music and Psychology Society. Music therapists work with a range of clients in schools and hospitals, using music listening or production to improve psychological and physical health. Unlike sound bath practitioners, music therapists are registered professionals with standardized training and ethical guidelines. The Social Connection Factor One potential benefit of sound baths that researchers acknowledge is the social aspect of the experience. "Historically, throughout most of human history... music has been about social connection," Garrido explains. "It's only in the last 100 years or so that we've had the capacity to go home and listen to music on our own in an isolating kind of way." The communal experience of a sound bath can create a sense of connection that's increasingly rare in our digital, often isolated lives. "Communally listening to music in the experience of a sound bath can be a 'helpful, healthy thing,'" Garrido adds. The Future of Sound Wellness As the wellness industry continues to evolve, sound baths may find their place alongside other mindfulness practices, though perhaps not as the "miracle cure" some marketing suggests. "I've been to them myself," Garrido admits. "I enjoy them, they can be relaxing, it's a nice experience – but I wouldn't pay too much money for it." The future of sound wellness likely involves a more balanced approach that acknowledges both the potential benefits of focused listening and the importance of not overclaiming what the science can support. As with many wellness trends, the key may be finding practices that work for individuals without requiring expensive or mystical explanations.

The Lead Doctors, scientists, and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference. Breakthroughs in Cancer Treatment The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year's theme, “the science and practice of translation: improving cancer outcomes worldwide”. Smart Drugs in Cancer Treatment Researchers have developed a smart drug that stops cancer cells hiding. The experimental tablet, GRWD5769, can help shrink tumours by at least 30% in six of the world’s most common forms of the disease, delegates in Chicago were told. 26 of 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers who were given GRWD5769 alongside cemiplimab had tumour reductions of at least 30%. 15 had tumour reductions of at least 30%. A Daily Pill for Pancreatic Cancer A pill that doubles survival time in patients with pancreatic cancer was presented at the conference. In a trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill, daraxonrasib, doubled survival time, with fewer side-effects compared with chemotherapy. Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy. Safely Skipping Some Treatments Some patients can safely skip some treatments, according to research presented at the conference. A genomic test could pave the way for a new era of personalised medicine, enabling doctors to determine which patients can safely skip chemotherapy. The Optima trial, led by University College London, followed 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. Those with a low score on the genomic test could be treated safely with hormone therapy alone. The Future of Cancer Treatment Urgent action is required to cope with rising cancer cases. The world faces a cancer workforce crisis, experts said, with a shortage of 100 million staff expected by 2050 when 100,000 people will be being diagnosed every day. A 21% increase in cancer incidence is predicted, according to a report presented at the conference. The rate is set to rise from 165 per 100,000 people in 2025 to 200 per 100,000 in 2050.

GLP‑1 Medications Show Promise in Reducing Breast Cancer IncidenceRecent analyses presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago suggest that patients using GLP‑1 receptor agonists—a class of weight‑loss drugs—experienced a 30% lower likelihood of being diagnosed with breast cancer compared with non‑users.Study cohort: 110,000 women aged 45‑80.Risk reduction: 30% for breast cancer onset.Lead researcher: Dr Elizabeth McDonald, University of Pennsylvania.Adjunctive Use of GLP‑1 Drugs Cuts Breast Cancer MortalityA separate investigation involving 27,000 breast‑cancer patients in Italy reported that adding a GLP‑1 agent to standard therapy was associated with a 30% decrease in cancer‑related death.Institution: IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.Outcome: 30% lower mortality risk.Broad Cancer‑Spread Benefits Observed Across Multiple Tumor TypesData from the Cleveland Clinic, covering 12,000 patients with breast, lung, colorectal or liver cancer, indicated a 38‑50% reduction in progression to stage‑four disease among GLP‑1 users.Study size: 12,000 patients.Risk reduction range: 38%–50% for metastatic spread.Why These Findings Matter for Public Health and OncologyThe consistency of risk‑reduction signals across incidence, mortality and metastasis points to a potential paradigm shift: drugs originally designed for diabetes and obesity may become adjunct tools in cancer prevention and treatment. If confirmed, the impact could be substantial given the prevalence of obesity and the high incidence of breast cancer worldwide.Next Steps: Clinical Trials and Regulatory ConsiderationsExperts caution that the current evidence is observational. Ongoing randomized controlled trials will be needed to disentangle the effects of weight loss from direct pharmacologic actions of GLP‑1 agonists. Regulatory bodies may eventually evaluate these agents for oncologic indications, pending robust trial data.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Lead: New Hope for Brain Injury RecoveryDr. Orlando Swayne, a consultant neurologist at the National Hospital for Neurology and Neurosurgery in London, is challenging the long-held medical belief that broken brains cannot mend. Through his pioneering work in neurorehabilitation, Swayne demonstrates that the brain's remarkable capacity for neuroplasticity can lead to meaningful recovery even years after severe brain injuries, offering new hope to patients who were once considered beyond help.The Case of Claire: A Journey from Severe Impairment to RecoveryClaire, a mother of three in her late 30s, experienced life-changing trauma when an artery at the base of her brain ruptured, causing severe damage to her frontal lobe. Initially brought to the ward on a stretcher, she was unable to speak, with flat eyes and an expressionless face. While she could move her right arm slightly, her left arm and both legs were immobile. When asked if she had any questions, she wrote with a clenched pencil: "Questions, questions, questions," revealing characteristic signs of brain damage through pathological repetition.The Science of Neuroplasticity: How the Brain Heals ItselfThe key to recovery lies in the brain's capacity for neuroplasticity—its ability to make new connections and reorganize in the face of changed circumstances. After a stroke or brain injury, chemical changes in the brain trigger neuronal growth processes that were last active during development. Surviving neurons are spurred into making new connections to work around dead tissue. While this process occurs naturally, targeted therapy can significantly enhance and guide it, leading to more substantial functional improvements.The Critical Window for Recovery: Timing MattersWhile the brain's capacity for plasticity is greatest in the first few months after injury, research shows that neuroplasticity doesn't simply switch off. In one study, intensive therapy improved upper limb movement in patients 18 months after their strokes. This finding is crucial as it extends the potential for recovery beyond the traditional "golden window" of the first few weeks or months, offering hope to those who may have missed early intervention opportunities.The Moral and Economic Imperative of NeurorehabilitationStroke is a leading cause of adult disability in the UK, with approximately 12 million people globally suffering a stroke each year, and one in five dying within 30 days. The economic and human costs of untreated brain injuries are enormous. Swayne argues that providing early, targeted, and intense therapy is not just a moral obligation but also an economic imperative, as proper rehabilitation can significantly reduce long-term care costs while dramatically improving patients' quality of life and independence.The Future of Brain Injury Treatment: Balancing Hope with RealismWhile Swayne emphasizes that recovery is possible, he is careful to balance hope with realism. "There is hope, but clearly you have to balance that. Some people just don't recover," he acknowledges. His approach represents a middle ground between the false promises of miracle cures and the previous hopelessness surrounding brain injuries. By focusing on evidence-based interventions and realistic expectations, Swayne and his colleagues are transforming the landscape of neurorehabilitation, offering meaningful improvements even for those with the most severe impairments.

Lionel Messi was the sole figure on the pitch during Argentina’s inaugural World Cup training session at their Kansas City base, a clear sign that the squad is meticulously managing fitness concerns ahead of the tournament. Solo Session Highlights Messi’s Fitness Focus The defending champions held their first pre‑tournament training on Monday, with the 38‑year‑old captain working on “specific exercises” while teammates with similar niggles joined physiotherapy staff. Messi has been coping with left hamstring fatigue since May 24, but the Argentine Football Association remains confident he will be ready for the opening match against Algeria on June 16 in Kansas City. Key Numbers Behind the Preparation Age: 38 International caps: 198 (all‑time Argentine leader) Goals for Argentina: 116 (all‑time record) Hamstring issue since: May 24 Next competitive match: June 9 vs Iceland (tune‑up in Auburn, Alabama) World Cup opener: June 16 vs Algeria Strategic Implications for Argentina’s Campaign By isolating Messi for targeted work, the coaching staff signals a dual strategy: preserve the star’s health while allowing the broader squad to maintain collective training intensity. This approach aims to minimize the risk of aggravating Messi’s hamstring, which could jeopardize Argentina’s attacking potency in a tournament where they are ranked #3 globally. Outlook: Messi’s Readiness and Argentina’s Prospects If Messi clears his fitness hurdle, Argentina enters the group stage with a fully fit talisman, boosting both morale and tactical flexibility. Conversely, any setback could force the team to rely more heavily on emerging talents, testing the depth built around Messi’s experience. The next week’s tune‑up against Iceland will serve as a litmus test for the squad’s overall health and cohesion.